SG11202109623WA - Combinations of anti-ildr2 antibodies and pd-1 antagonists - Google Patents

Combinations of anti-ildr2 antibodies and pd-1 antagonists

Info

Publication number
SG11202109623WA
SG11202109623WA SG11202109623WA SG11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA
Authority
SG
Singapore
Prior art keywords
antagonists
combinations
ildr2
antibodies
ildr2 antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Lars Röse
Uwe Gritzan
Spencer Liang
Andrew Pow
John Hunter
Ofer Levy
Ilan Vaknin
Original Assignee
Bayer Ag
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Compugen Ltd filed Critical Bayer Ag
Publication of SG11202109623WA publication Critical patent/SG11202109623WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202109623W 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists SG11202109623WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832320P 2019-04-11 2019-04-11
PCT/EP2020/059745 WO2020207961A1 (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Publications (1)

Publication Number Publication Date
SG11202109623WA true SG11202109623WA (en) 2021-10-28

Family

ID=70224379

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109623W SG11202109623WA (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Country Status (15)

Country Link
US (1) US20220169736A1 (zh)
EP (1) EP3952910A1 (zh)
JP (1) JP2022528472A (zh)
KR (1) KR20210151808A (zh)
CN (1) CN113645999A (zh)
AR (1) AR118621A1 (zh)
AU (1) AU2020271352A1 (zh)
BR (1) BR112021020148A2 (zh)
CA (1) CA3136510A1 (zh)
IL (1) IL287093A (zh)
MX (1) MX2021012406A (zh)
PE (1) PE20212271A1 (zh)
SG (1) SG11202109623WA (zh)
TW (1) TW202104275A (zh)
WO (1) WO2020207961A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
LT2769729T (lt) * 2007-09-04 2019-05-10 Compugen Ltd. Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
KR20140126357A (ko) * 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
KR20200096223A (ko) * 2017-11-30 2020-08-11 바이엘 악티엔게젤샤프트 Ildr2 길항제 및 그의 조합물

Also Published As

Publication number Publication date
PE20212271A1 (es) 2021-11-30
TW202104275A (zh) 2021-02-01
KR20210151808A (ko) 2021-12-14
CA3136510A1 (en) 2020-10-15
WO2020207961A1 (en) 2020-10-15
AU2020271352A8 (en) 2022-04-07
JP2022528472A (ja) 2022-06-10
MX2021012406A (es) 2022-01-19
EP3952910A1 (en) 2022-02-16
IL287093A (en) 2021-12-01
US20220169736A1 (en) 2022-06-02
AU2020271352A1 (en) 2021-10-07
BR112021020148A2 (pt) 2021-12-21
CN113645999A (zh) 2021-11-12
AR118621A1 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
IL276340A (en) PD-1 agonistic antibodies and their uses
IL276731A (en) Antibodies against CD73 and methods of using them
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
ZA202000051B (en) Antibodies that specifically bind pd-1 and methods of use
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL278821A (en) Anti-SIRPA antibodies and methods of using them
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL287282A (en) Anti-mertk antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL282424A (en) ALK2 antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
PL3430054T3 (pl) Sposoby leczenia nowotworów z zastosowaniem antagonistów wiązania z osią PD-1 i przeciwciał anty-GPC3
EP3676294A4 (en) ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
EP4061848A4 (en) ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
IL288886A (en) Antibodies and methods of use